Boehringer Ingelheim struck a backloaded, potentially $7 billion-plus cancer development agreement with China’s Sino Biopharmaceutical. The report highlights Boehringer’s continued expansion strategy in China through a deal structure designed to scale payments with development and commercialization milestones. The collaboration is centered on an antibody-drug conjugate and therapy combination platform (described as an ADC and TCE cancer drug development program). Boehringer is delivering an initial payment of $358 million, with the overall economics depending on future progress. For biotech industry watchers, the transaction underscores how major Western companies are underwriting oncology platform exposure in China amid competitive ADC pipelines and rising local development activity.